Imatinib

SKU: orb1300957

Description

Imatinib

Research Area

Cardiovascular Research, Cell Biology, Infectious Disease & Virology, Signal Transduction

Key Properties

• CAS Number: 152459-95-5
• MW: 493.6
• Purity: 99.85%
• Formula: C₂₉H₃₁N₇O
• SMILES: CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC(=CC=N3)C3=CC=CN=C3)=C(C)C=C2)CC1
• Target: Autophagy,Bcr-Abl,PDGFR,SARS-CoV,c-Kit
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:2.5 mg/mL (5.06 mM);DMSO:25 mg/mL (50.65 mM)

Bioactivity

• Target IC50:
  BV-173 cells:20 μM|MG-63 cells:20 μM|ASPC1 cells:44 μM|PDGFR:100 nM (cell free)|POS-1 cells:15 μM|A10 cells:162 nM|c-Kit:100 nM (cell free)|HOS cells:11 μM|OSRGA cells:9 μM|MOS-J cells:23 μM|A2780 cells:48 μM|A431 cells:31 μM|BaF3 cells:> 1 μM|BaF3 cells:> 10 μM A549 cells:> 25 μM
• In Vivo:
  METHODS: To investigate antitumor activity, Imatinib (25-100 mg/kg) was administered orally to mice bearing undifferentiated POS-1 or mixed osteoblast/osteolytic MOS-J osteosarcoma tumors once daily for 21 or 43 days. Results: Imatinib inhibited osteosarcoma progression in vivo METHODS: To stud the effects on multiple sclerosis (MS), Imatinib (60 mg/kg) was administered orally Six times per week for two weeks to an EAE C57BL/6 mouse model. Results: Imatinib had beneficial effects on EAE by reducing disease severity and delaying onset.Imatinib and its potential therapeutic effects and immunomodulatory properties may be considered fo the treatment of multiple sclerosis.
• In Vitro:
  METHODS: Human, mouse and rat osteosarcoma cells were treated with Imatinib (1-40 μM) for 72 h, and cell viability was measured using XTT assay. Results: Imatinib reduce the number of live osteosarcoma cells in a dose-dependent manner, with 72 h IC50 of 20 μM (MG-63), 11 μM (HOS), 23 μM (MOS-J), 15 μM (POS-1), and 9 μM (OSRGA). METHODS: Human gastric cancer cells AGS, MKN45 and SNU638 were treated with Imatinib (30-100 μM) for 48 h. Apoptosis was detected using Flow Cytometry. Results the percentage of Annexin V/PI-positive cells was significantly increased, indicating that Imatinib treatment increased early apoptosis of tumor cells.
• Cell Research:
  M-07e cells were grown in serum-free RPMI 1640 at 37℃or approximately 18 hours before they were incubated for 90 minutes in the presence of various concentration of STI 571 the cells were then pelleted and resuspended in 1 mL RPMI 1640. STI 571 was added to Each tube to achiev the same concentration used durin the 90 minutes of preincubation the cells were then incubated with inhibitor and growth factor (SLF or GM-CSF) for 15 minutes at 37℃. Subsequently the cell pellets were lysed with 100 to 250 μL of protein lysis buffer (50 mmol/L Tris, 150 mmol/L sodium chloride, 1% NP-40, and 0.25% deoxycholate, with addition o the inhibitors aprotinin, leupeptin, pepstatin, phenylmethyl sulfonyl fluoride, and sodium orthovanadate). Western immunoblot analysis was performed as previously described.41Experiments with HMC-1 cells were performed in the same way except that neither SLF nor GM-CSF was added.
• Animal Research:
  Swiss mice (nu/nu, f Male), weighing 30 g, 6 – 8 weeks old, were bred in the animal facilities, maintained under specific pathogen-free conditions with artificial lighting (12 hr light/12 hr dark cycle) and fed a regular diet and water ad libitum. For therapeutic trials the tumor-bearing mice were andomly divided into equivalent groups of 5 to 12 animals and mice were treated as soon a the xenografted tumors reached a diameter of 5 mM (or a tumor volume of approximately 60 mm^3). Four different human tumors were used the SCLC6, SCLC61, SCLC 74 and SCLC108 s All cell lung cancers. STI571 was administered at a total dosage of 70 or 100 mg/kg per day in 1 or 2 intraperitoneal injections, with or without etoposide plus ifosfamide or topotecan. STI571 was diluted in 150 l of H2O and administered on different days, as indicated. Etoposide and ifosfamide were diluted in 200 l of 0.9% sodium chloride, and topotecan was diluted in 150 l of 0.9% sodium chloride the control group received injections according to the same schedule as Experimentally treated mice. All mice were weighed once weekly. Tumor growth was monitored by measuring 2 perpendicular diameters with calipers. Tumor volume (V) an the relative tumor volume (RTV) were calculated as:. V = a^2 × b/2,. where a in the width (large diameter) and the length (small. diameter) o the tumor in millimeters, and RTV = Vx/Vi,. where Vx in the mean tumor volume in cubic millimeters at any given time and Vi in the mean initial tumor volume in cubic millimeters a the start of treatment. Mice were ethically sacrificed whe the tumor volume reached 2,500 mm^3.

Storage & Handling

• Storage: store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Disclaimer: For research use only

Alternative Names

Bcr-Abl, BcrAbl, Autophagy, cKit, c-Kit, CD117, CGP057148B, CGP-57148B, Inhibitor, Imatinib, inhibit, Platelet-derived growth factor receptor, PDGFR, ST1571, ST-1571, ST 1571, SCFR, SARSCoV, SARS coronavirus, SARS-CoV, STI 571, STI571, STI-571, v-Abl

Compound Identifiers

PubChem CID

5291

References

A Cama Fabio Verginelli, Silvia Perconti, Simone Vespa, Francesca Schiavi, Sampath Chandra Prasat, Paola Lanuti gruppootologico.com, (2024)

PubMed: